Salari H, Duronio V, Howard S, Demos M, Pelech S L
Department of Medicine, University of British Columbia, Vancouver, Canada.
Biochem J. 1990 May 1;267(3):689-96. doi: 10.1042/bj2670689.
The relationship between polyphosphoinositide hydrolysis and protein kinase C (PKC) activation was explored in rabbit platelets treated with the agonists platelet-activating factor (PAF), thrombin and 12-O-tetradecanoylphorbol 13-acetate (TPA), and with the anti-aggregant prostacyclin (PGI2). Measurement of the hydrolysis of radiolabelled inositol-containing phospholipids relied upon the separation of the products [3H]inositol mono-, bis- and tris-phosphates by Dowex-1 chromatography. PKC activity, measured in platelet cytosolic and Nonidet-P40-solubilized particulate extracts that were fractionated by MonoQ chromatography, was based upon the ability of the enzyme to phosphorylate either histone H1 in the presence of the activators Ca2+, diacylglycerol and phosphatidylserine, or protamine in the absence of Ca2+ and lipid. Treatment of platelets for 1 min with PAF (2 nM) or thrombin (2 units/ml) led to the rapid hydrolysis of inositol-containing phospholipids, a 2-3-fold stimulation of both cytosolic and particulate-derived PKC activity, and platelet aggregation. Exposure to TPA (200 nM) for 5 min did not stimulate formation of phosphoinositides, but translocated more than 95% of cytosolic PKC into the particulate fraction, and induced a slower rate of aggregation. PGI2 (1 microgram/ml) did not enhance phosphoinositide production, and at higher concentrations (50 micrograms/ml) it antagonized the ability of PAF, but not that of thrombin, to induce inositol phospholipid turnover, even though platelet aggregation in response to both agonists was blocked by PGI2. On the other hand, PGI2 alone also appeared to activate (by 3-5-fold) cytosolic and particulate PKC by a translocation-independent mechanism. The activation of PKC by PGI2 was probably mediated via cyclic AMP (cAMP), as this effect was mimicked by the cAMP analogue 8-chlorophenylthio-cAMP. It is concluded that this novel mechanism of PKC regulation by platelet agonists may operate independently of polyphosphoinositide turnover, and that activation of cAMP-dependent protein kinase represents another route leading to PKC activation.
在分别用激动剂血小板活化因子(PAF)、凝血酶、12 - O - 十四烷酰佛波醇13 - 乙酸酯(TPA)以及抗聚集剂前列环素(PGI2)处理的兔血小板中,研究了多磷酸肌醇水解与蛋白激酶C(PKC)激活之间的关系。放射性标记的含肌醇磷脂的水解测定依赖于通过Dowex - 1色谱法分离产物[3H]肌醇单磷酸、双磷酸和三磷酸。通过MonoQ色谱法分级分离的血小板胞质和Nonidet - P40增溶颗粒提取物中测定的PKC活性,是基于该酶在激活剂Ca2 +、二酰基甘油和磷脂酰丝氨酸存在下使组蛋白H1磷酸化的能力,或者在不存在Ca2 +和脂质的情况下使鱼精蛋白磷酸化的能力。用PAF(2 nM)或凝血酶(2单位/毫升)处理血小板1分钟导致含肌醇磷脂的快速水解,胞质和颗粒来源的PKC活性均有2 - 3倍的刺激,以及血小板聚集。暴露于TPA(200 nM)5分钟未刺激磷酸肌醇的形成,但使超过95%的胞质PKC转位到颗粒部分,并诱导较慢的聚集速率。PGI2(1微克/毫升)未增强磷酸肌醇的产生,并且在较高浓度(50微克/毫升)时它拮抗PAF诱导肌醇磷脂周转的能力,但不拮抗凝血酶的这种能力,尽管PGI2阻断了对两种激动剂的血小板聚集反应。另一方面,单独的PGI2似乎也通过一种不依赖转位的机制激活(3 - 5倍)胞质和颗粒PKC。PGI2对PKC的激活可能是通过环磷酸腺苷(cAMP)介导的,因为这种作用被cAMP类似物8 - 氯苯硫基 - cAMP模拟。得出的结论是,血小板激动剂对PKC的这种新调节机制可能独立于多磷酸肌醇周转起作用,并且cAMP依赖性蛋白激酶的激活代表了导致PKC激活的另一条途径。